KRTL now Pink Current on updated filing: KRTL amended https://www.otcmarkets.com/otcapi/company/fin...18/content Describe the issuers’ principal products or services.
The Company operates through multiple subsidiaries and affiliated entities, each serving distinct strategic and
operational functions within the Company’s pharmaceutical, agricultural, and intellectual property (IP) portfolios.
Active Subsidiaries:
• KRTL Biotech Inc. – A U.S.-based pharmaceutical entity, FDA-registered, focused on the commercialization of
APIs and licensing agreements within the pharmaceutical and nutraceutical sectors.
• KRTL International Corp. – Specializing in international trade, agricultural technology solutions, and production
scaling strategies aligned with FDA and global quality standards.
Affiliated Companies and Strategic Entities:
• KRTL Xylem Inc. (est. 2024) subsidiary of KRTL International Corp
• Periko Corp. (est. 2024) subsidiary of KRTL Biotech Inc. 33% owned
• Rayel Corp. (est. 2024) subsidiary of KRTL Biotech Inc 33% owned
These three companies were initially established to house intellectual property (IP) portfolios. Based on recent internal
assessments, these entities may be more appropriately designated as Special Purpose Entities (SPEs), given their
specific function in IP holding and asset protection.
• SGMARTL Corp. (est. 2025) – Formed as part of a joint venture structure with Sigma Corp, this entity facilitates
collaborative pharmaceutical development and market expansion under the SGMARTL Agreement. SGMARTL
also manages the earnings split with Sigma for U.S. sales of APIs, pharmaceutical products, and medicines,
ensuring equitable revenue distribution and financial compliance.
• Gemini Global Solutions LLC (est. October 2024) – A joint venture entity formed in partnership with Earthmed
LLC to support cross-border logistics, technology transfer, and financial integration projects. The Company rents office space at 14143 Denver W Pkwy #100 Golden, CO 80401. It utilizes a manufacturing facility in
Bolivia operated by Industria Químico Farmacéutica Sigma Corp. S.R.L.
The Company operates through multiple subsidiaries and affiliated entities, each serving distinct strategic and
operational functions within the Company’s pharmaceutical, agricultural, and intellectual property (IP) portfolios.
Active Subsidiaries:
• KRTL Biotech Inc. – A U.S.-based pharmaceutical entity, FDA-registered, focused on the commercialization of
APIs and licensing agreements within the pharmaceutical and nutraceutical sectors.
• KRTL International Corp. – Specializing in international trade, agricultural technology solutions, and production
scaling strategies aligned with FDA and global quality standards.
Affiliated Companies and Strategic Entities:
• KRTL Xylem Inc. (est. 2024) subsidiary of KRTL International Corp
• Periko Corp. (est. 2024) subsidiary of KRTL Biotech Inc. 33% owned
• Rayel Corp. (est. 2024) subsidiary of KRTL Biotech Inc 33% owned
These three companies were initially established to house intellectual property (IP) portfolios. Based on recent internal
assessments, these entities may be more appropriately designated as Special Purpose Entities (SPEs), given their
specific function in IP holding and asset protection.
• SGMARTL Corp. (est. 2025) – Formed as part of a joint venture structure with Sigma Corp, this entity facilitates
collaborative pharmaceutical development and market expansion under the SGMARTL Agreement. SGMARTL
also manages the earnings split with Sigma for U.S. sales of APIs, pharmaceutical products, and medicines,
ensuring equitable revenue distribution and financial compliance.
• Gemini Global Solutions LLC (est. October 2024) – A joint venture entity formed in partnership with Earthmed
LLC to support cross-border logistics, technology transfer, and financial integration projects. The Company rents office space at 14143 Denver W Pkwy #100 Golden, CO 80401. It utilizes a manufacturing facility in
Bolivia operated by Industria Químico Farmacéutica Sigma Corp. S.R.L.
